Sorafenib plus selective internal radiotherapy with ⁹⁰Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial.

ABSTRACT:

Introduction

Selective internal radiation therapy (SIRT) and sorafenib are used for patients with liver metastases from uveal melanoma. We conducted a phase I study to determine the optimal timing of administration of sorafenib in combination with radioembolisation.

Methods

Patients received radioembolisation plus sorafenib initiated 14, 11, or 3 days after or 7 days before radioembolisation. The primary endpoint was safety. Secondary endpoints included efficacy and evaluation of circulating angiogenic factors. Sorafenib plasma levels were quantified retrospectively.

Results

Ten patients received radioembolisation plus sorafenib. The most common grade 2-4 adverse events included rash, abdominal pain, fatigue and lymphocytopenia. Best response was partial response (30%

SUBMITTER: Berthod G 

PROVIDER: S-EPMC12858916 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature